A long-acting analog of amylin, the satiety hormone co-secreted with insulin, researched for obesity both alone and combined with semaglutide (CagriSema).
Investigational — phase 3. Not approved as a standalone medicine.
Also known as: AM833
Cagrilintide mimics amylin and acts as an agonist at brain amylin receptors AMY1 and AMY3 — calcitonin-receptor cores paired with receptor-activity-modifying proteins — in the hindbrain and hypothalamus. Through these it engages both homeostatic and reward-related appetite circuits, reducing food intake. It also slows gastric emptying and promotes satiety, a pathway distinct from GLP-1 signalling, which is why the two add together rather than overlap. Acylation extends its half-life enough for once-weekly use.
In the phase 3 REDEFINE programme, cagrilintide alone produced roughly 11.8% body-weight reduction at 68 weeks versus about 2.5% on placebo. Combined with semaglutide (CagriSema), mean reduction reached about 20.4% at 68 weeks, beating semaglutide alone (~14.9%) and cagrilintide alone (~11.5%) — evidence of a genuinely additive dual-pathway effect. Mechanistic work confirmed brain amylin receptors AMY1 and AMY3 mediate the weight effect.
We report both positive and negative trial results. For exact study protocols, read the sources — we cite them rather than repackage them.
Bars reflect the strength & volume of research evidence for each use — not a guarantee of results.
Predominantly gastrointestinal, as with the amylin and incretin class — nausea, vomiting and constipation — usually mild to moderate and most frequent during dose escalation in trials. Injection-site reactions were also reported.
Semaglutide — additive: amylin-receptor satiety plus GLP-1 signalling suppress appetite more than either alone (the CagriSema rationale). Tirzepatide — discussed comparatively as a rival multi-pathway approach.
Mechanistic context only — we don't publish combinations, amounts or protocols.
Closest to pramlintide, the first-generation amylin analog, but acylation gives cagrilintide a far longer half-life. Versus semaglutide it works through amylin rather than incretin receptors — a different pathway, which is exactly why the combination outperforms either.
No. It is an amylin analog acting on amylin receptors — a separate satiety pathway that can add to GLP-1 effects.
A fixed combination of cagrilintide and semaglutide, studied for greater weight loss than either component alone.
Not as of the latest available data — it remains investigational in phase 3.
No reviews yet. If you've used Cagrilintide, be the first to share what it helped with and any side effects.
⚠️ Educational research information only — not medical advice. Many peptides are sold strictly for laboratory research and are not approved treatments. The evidence scores reflect research interest and strength, not efficacy or safety for any individual. Always consult a qualified professional.